Evolent Health Inc (NYSE: EVH) has reported a loss for its first fiscal quarter (ending March 31) of $-0.22 versus a loss $-0.24 for the same period a year ago. Relative to the consensus estimate of $0.37, this was a shortfall of $-0.59. E.P.S. were $-1.25 for the latest four quarters through March 31 versus $-0.38 for the same period a year ago.
Recent Price Action
On 5/9/24, Evolent Health Inc (NYSE: EVH) stock declined modestly by -1.1%, closing at $26.96. Moreover, this decline was accompanied by unusually high trading volume at 196% of normal. The stock has declined -1.1% during the last week but has been strong relative to the market over the last nine months.
Current PriceTarget Research Rating
EVH’s future returns on capital are forecasted to exceed the cost of capital. Accordingly, the company is expected to continue to be an important Value Builder.
Evolent Health has a current Value Trend Rating of C (High Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing inconsistent signals. Evolent Health has a neutral Appreciation Score of 43 but a good Power Rating of 76, leading to the High Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment